Oliver Law Firm Auction Team: An example of why they do what they do.

Oliver Law Firm Auction Team is honored to support nonprofit organizations in Northwest Arkansas.  The all-volunteer team have helped raise almost $3 million for local and national research, equipment, programing, facilities and an extensive list of other needs.  Tonight, the Auction Team will be donating their time to the Cystic Fibrosis Foundation during their annual Wine Opener fundraiser.

The new FDA approved therapy Trikafta for CF patients is a great example of how proceeds from events like the Wine Opener are used for generating evolutionary research.  The Auction Team will be working hard to raise bids and raise money during tonight’s live auction.  We hope you are planning to attend the Wine Opener.  Your donations really do make a difference.  Read the following news releases for proof of how your money can help create research with life-changing results.

——————-

FDA approves new breakthrough therapy for cystic fibrosis. 

Treatment approved for approximately 90% of patients with cystic fibrosis, many of whom had no approved therapeutic options.

FDA NEWS RELEASE – October 21, 2019

The U.S. Food and Drug Administration today approved Trikafta (elexacaftor/ivacaftor/tezacaftor), the first triple combination therapy available to treat patients with the most common cystic fibrosis mutation. Trikafta is approved for patients 12 years and older with cystic fibrosis who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which is estimated to represent 90% of the cystic fibrosis population.

Cystic Fibrosis Foundation, Published October 21, 2019

Today marks a tremendous breakthrough and exciting news for people with cystic fibrosis. The U.S. Food and Drug Administration (FDA) approved Trikafta™ for people with cystic fibrosis who have at least one copy of the F508del mutation. With the approval of Trikafta, more than 90 percent of people with CF could eventually have a highly effective therapy for the underlying cause of their disease. Until now, most people with a single copy of the F508del mutation did not have an approved treatment for the underlying cause of CF.

“Today marks a tremendous breakthrough and exciting news for people with cystic fibrosis,” said Preston W. Campbell, III, M.D., president and CEO of the Cystic Fibrosis Foundation. “This milestone is the result of an extraordinary community working together against great odds, and we are overjoyed that this will mean more people will have effective treatments for their disease.”